This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
Lei Jun: the second phase of Xiaomi smart factory is expected to start production by the end of next year
Hong Kong IPO at a Glance: Weibo Corporation
The Twitter-like platform completed its secondary listing on December 8, 2021.
Dec 08, 2021 10:03 PM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
Yesterday 12:51 PM